Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial

May 3, 2021 Leave a comment
 A number of energetic vaccination approaches have confirmed ineffective in lowering the substantial morbidity and mortality attributable to respiratory syncytial virus (RSV) in infants and older adults (aged ≥65 years). A vaccine conferring a considerable and sustainable enhance in neutralising exercise is required to guard towards extreme RSV illness. To that finish, we evaluated the security and immunogenicity of DS-Cav1, a prefusion F subunit vaccine. On this part 1 research, DS-Cav1 vaccination was secure and effectively tolerated. DS-Cav1 vaccination elicited a strong enhance in RSV F-specific antibodies and neutralising exercise that was sustained above baseline for no less than 44 weeks.

On this randomised, open-label, part 1 scientific trial, the stabilised prefusion F vaccine DS-Cav1 was evaluated for dose, security, tolerability, and immunogenicity in wholesome adults aged 18-50 years at a single US web site. Individuals had been assigned to obtain escalating doses of both 50 μg, 150 μg, or 500 μg DS-Cav1 at weeks Zero and 12, and had been randomly allotted in a 1:1 ratio inside every dose group to obtain the vaccine with or with out aluminium hydroxide (AlOH) adjuvant. A single low-dose of pre-F immunisation of antigen-experienced people may confer safety that extends all through a complete RSV season.

After 71 individuals had been randomised, the protocol was amended to permit some individuals to obtain a single vaccination at week 0. The first goals evaluated the security and tolerability at each dose inside 28 days following every injection. Neutralising exercise and RSV F-binding antibodies had been evaluated from week Zero to week 44 as secondary and exploratory goals. Security was assessed in all individuals who acquired no less than one vaccine dose; secondary and exploratory immunogenicity evaluation included all individuals with out there knowledge at a given go to.

European knowledge sources for computing burden of (potential) vaccine-preventable illnesses in ageing adults

To information decision-making on immunisation programmes for ageing adults in Europe, one of many goals of the Vaccines and InfecTious illnesses within the Ageing popuLation (IMI2-VITAL) venture is to evaluate the burden of illness (BoD) of (doubtlessly) vaccine-preventable illnesses ((P)VPD). We aimed to establish the out there knowledge sources to calculate the BoD of (P)VPD in taking part VITAL international locations and to pinpoint knowledge gaps. Primarily based on epidemiological standards and vaccine availability, we prioritized (P) VPD attributable to Further-intestinal pathogenic Escherichia coli (ExPEC), norovirus, respiratory syncytial virus, Staphylococcus aureus, and pneumococcal pneumonia.

Morbidity and mortality knowledge had been typically out there for all 5 illnesses, whereas abstract BoD estimates had been largely missing. Out there knowledge weren’t all the time stratified by age and danger group, which is very necessary when calculating BoD for ageing adults. AMR knowledge had been out there in a number of international locations for S. aureus and ExPEC. This research offers an exhaustive overview of the out there knowledge sources and knowledge gaps for the estimation of BoD of 5 (P) VPD in ageing adults within the EU/EAA, which is helpful to information pathogen-specific BoD research and contribute to calculation of (P)VPDs BoD.

Respiratory syncytial virus (RSV) is a typical pathogen inflicting extreme respiratory sickness in infants and elder adults. The event of an efficient RSV vaccine is a crucial unmet medical want and an space of energetic analysis. The normal methodology for testing neutralizing antibodies towards RSV in scientific trials is the plaque discount neutralization take a look at (PRNT), which makes use of 24-well plates and wishes six days publish an infection to develop viral plaques.

On this research, we’ve got developed a virus discount neutralization take a look at (VRNT), which permits the variety of RSV contaminated cells to be routinely counted by an imaging cytometer at someday publish an infection in 96-well plates. VRNT was discovered sturdy to cell seeding density, detection antibody focus, virus enter and an infection time.

Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial

Balancing Precision vs. Cohort Transcriptomic Evaluation of Acute and Restoration Part of Viral Bronchiolitis

Viral infections affecting the decrease respiratory tract place monumental burdens on hospitals. As neither vaccines nor anti-viral brokers exist for a lot of viruses, understanding danger elements and outcomes in every affected person utilizing minimally invasive evaluation, similar to blood, can result in improved healthcare supply. A cohort of PAXGene RNAseq of infants admitted with reasonable or extreme acute bronchiolitis and respiratory syncytial virus (RSV) had been in contrast with case-control statistical evaluation and cohort-based outlier mapping for precision transcriptomics.

Extreme bronchiolitis sufferers had signatures linked to the immune system, interferon signaling, and cytokine signaling, with marked intercourse variations in XIST, RPS4Y1, KDM5D, and LINC00278 for severity. A number of sufferers had distinctive secondary infections, cytokine activation, immune responses, organic pathways, and immune cell activation, highlighting the necessity for outlining patient-level transcriptomic signatures. Balancing relative contributions of cohort-based biomarker discoveries with affected person’s organic responses is required to grasp totality of mechanisms of hostile outcomes in viral bronchiolitis.

Recombinant Virus VEGF E (Orf Virus) Protein, His, E.coli-2ug
QP10912-2ug 2ug
EUR 155

VEGF-E Vascular Endothelial Growth Factor-E Recombinant Protein(Orf Virus)
PROTQ2F842 Regular: 10ug
EUR 317
Description: A DNA sequence encoding the mature variant of ovVEGF-E isolate D1701 (Dehio et al., 1999; GenBank accession No. AF106020) was expressed in E. coli as a 132 amino acid residue fusion protein with an N-terminal His-tag sequence and a thrombin cleavage site. Recombinant VEGF-E homodimer was dimerized in vitro and has a predicted mass of approximately 35 kDa.

Hepatitis E virus ORF 2 recombinant antigen
8942 100 ug
EUR 398
Description: This is Hepatitis E virus ORF 2 recombinant antigen for ELISA,WB.

Hepatitis E virus ORF 2 recombinant antigen
8943 100 ug
EUR 398
Description: This is Hepatitis E virus ORF 2 recombinant antigen for ELISA,WB.

Hepatitis E virus ORF 3 recombinant antigen
8944 100 ug
EUR 398
Description: This is Hepatitis E virus ORF 3 recombinant antigen for ELISA,WB.

Hepatitis E virus ORF 3 Recombinant Protein
53-335 0.01 mg
EUR 542.75
Description: Hepatitis E virus ORF 3 Recombinant Protein

Hepatitis E virus ORF 2 Recombinant Protein
53-336 0.01 mg
EUR 542.75
Description: Hepatitis E virus ORF 2 Recombinant Protein

Hepatitis E virus ORF 2 Recombinant Protein
53-337 0.01 mg
EUR 542.75
Description: Hepatitis E virus ORF 2 Recombinant Protein

Rabbit Polyclonal antibody Anti-CRBN
Anti-CRBN 50 µg
EUR 349

Anti-Zika Virus Envelope Protein E Antibody
STJ503579 100 µg
EUR 476

Recombinant Vascular Endothelial Growth Factor-E (Orf Virus)
7-01759 2µg Ask for price

Recombinant Vascular Endothelial Growth Factor-E (Orf Virus)
7-01760 10µg Ask for price

Recombinant Vascular Endothelial Growth Factor-E (Orf Virus)
7-01761 1mg Ask for price

Vascular Endothelial Growth Factor-E (Orf Virus) Protein
20-abx263083
  • EUR 328.00
  • EUR 8652.00
  • EUR 230.00
  • 10 ug
  • 1 mg
  • 2 µg

Hepatitis E Virus antibody
70R-HR003 100 ug
EUR 349
Description: Affinity purified Rabbit polyclonal Hepatitis E Virus antibody

Hepatitis E Virus protein
30-AH29 1 mg
EUR 997
Description: Hepatitis E Virus recombinant protein

Hepatitis E Virus protein
30R-AH054X 500 ug
EUR 1153
Description: Hepatitis E Virus Mosaic recombinant protein

Deoxybrevianamide E
D083-1MG 1 mg
EUR 278

Deoxybrevianamide E
D083-5MG 5 mg
EUR 897

Cytochalasin E
C197-1MG 1 mg
EUR 131

Cytochalasin E
C197-5MG 5 mg
EUR 385

Paraherquamide E
P070-0.5MG 0.5 mg
EUR 400

Paraherquamide E
P070-2.5MG 2.5 mg
EUR 1325

Phenelfamycin E
P078-1MG 1 mg
EUR 318

Phenelfamycin E
P078-5MG 5 mg
EUR 1040

Oligomycin E
O021-1MG 1 mg
EUR 318

Oligomycin E
O021-5MG 5 mg
EUR 1040

Roquefortine E
R035-1MG 1 mg
EUR 224

Roquefortine E
R035-5MG 5 mg
EUR 708

Anti-Zika Virus Envelope (E) Protein monoclonal Antibody
CABT-B8528 1 mg
EUR 887

Anti-Zika Virus Envelope Protein E Antibody BIOTIN
STJ503580 100 µg
EUR 586

Anti-Zika Virus Envelope Protein E Antibody FITC
STJ503581 100 µg
EUR 586

Anti-VEGF antibody
STJ97787 200 µl
EUR 197
Description: Rabbit polyclonal to VEGF.

Anti-VEGF antibody
STJ119887 100 µl
EUR 393
Description: This gene is a member of the PDGF/VEGF growth factor family. It encodes a heparin-binding protein, which exists as a disulfide-linked homodimer. This growth factor induces proliferation and migration of vascular endothelial cells, and is essential for both physiological and pathological angiogenesis. Disruption of this gene in mice resulted in abnormal embryonic blood vessel formation. This gene is upregulated in many known tumors and its expression is correlated with tumor stage and progression. Elevated levels of this protein are found in patients with POEMS syndrome, also known as Crow-Fukase syndrome. Allelic variants of this gene have been associated with microvascular complications of diabetes 1 (MVCD1) and atherosclerosis. Alternatively spliced transcript variants encoding different isoforms have been described. There is also evidence for alternative translation initiation from upstream non-AUG (CUG) codons resulting in additional isoforms. A recent study showed that a C-terminally extended isoform is produced by use of an alternative in-frame translation termination codon via a stop codon readthrough mechanism, and that this isoform is antiangiogenic. Expression of some isoforms derived from the AUG start codon is regulated by a small upstream open reading frame, which is located within an internal ribosome entry site.

anti- VEGF antibody
FNab09391 100µg
EUR 548.75
Description: Antibody raised against VEGF

Anti- VEGF antibody
FNab09933 100µg
EUR 548.75
Description: Antibody raised against VEGF

Anti-VEGF antibody
PAab09391 100 ug
EUR 386

Hepatitis E virus PCR kit
PCR-H498-48R 50T
EUR 823

Hepatitis E virus PCR kit
PCR-H498-96R 100T
EUR 1113

Recombinant Hepatitis E Virus ORF3 
7-07450 100µg Ask for price

Recombinant Hepatitis E Virus ORF3 
7-07451 500µg Ask for price

Recombinant Hepatitis E Virus ORF3 
7-07452 1000µg Ask for price

Hepatitis E Virus ORF3 Protein
20-abx260138
  • EUR 885.00
  • EUR 342.00
  • EUR 1372.00
  • 0.5 mg
  • 100 ug
  • 1 mg

Recombinant Zika Virus E Protein
VAng-Lsx0581-100g 100 µg
EUR 1138
Description: Zika Virus Envelope, recombinant protein from Insect cells.

Hepatitis E Virus protein (HRP)
65-IH35 1 ml
EUR 1105
Description: Purified recombinant Hepatitis E Virus protein (HRP)

Mouse anti- hepatitis E virus IgM antibody ELISA Kit
ELA-E1791m 96 Tests
EUR 865

Human vascular endothelial cell growth factor E, VEGF-E ELISA Kit
CSB-E15022h-24T 1 plate of 24 wells
EUR 165
Description: Quantitativesandwich ELISA kit for measuring Human vascular endothelial cell growth factor E, VEGF-E in samples from serum, urine, cell culture supernates, tissue homogenates. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price.

Human vascular endothelial cell growth factor E, VEGF-E ELISA Kit
1-CSB-E15022h
  • EUR 678.00
  • EUR 4644.00
  • EUR 2467.00
  • 1 plate of 96 wells
  • 10 plates of 96 wells each
  • 5 plates of 96 wells each
Description: Quantitativesandwich ELISA kit for measuring Human vascular endothelial cell growth factor E, VEGF-E in samples from serum, urine, cell culture supernates, tissue homogenates. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits.

Anti-VEGF/VEGFA Antibody
PA1080 100ug/vial
EUR 334

Anti-VEGF/VEGFA Antibody
PB9071 100ug/vial
EUR 334

Anti-VEGF/VEGF164 Antibody
A00045-1 100ug/vial
EUR 294

Anti-VEGF/Vegfa Antibody
A00045-2 100ug/vial
EUR 294

Anti-VEGF-C Antibody
A00623 100ul
EUR 397
Description: Rabbit Polyclonal Antibody for VEGF-C Antibody (VEGFC) detection.tested for IHC, WB in Human, Mouse, Rat.

Anti-VEGF-C antibody
STJ96662 200 µl
EUR 197
Description: Rabbit polyclonal to VEGF-C.

Anti-VEGF-B antibody
STJ96851 200 µl
EUR 197
Description: Rabbit polyclonal to VEGF-B.

anti-VEGF Receptor 1
YF-PA11817 50 ug
EUR 363
Description: Mouse polyclonal to VEGF Receptor 1

anti-VEGF Receptor 1
YF-PA11818 100 ug
EUR 403
Description: Rabbit polyclonal to VEGF Receptor 1

anti-VEGF Receptor 3
YF-PA23727 50 ul
EUR 334
Description: Mouse polyclonal to VEGF Receptor 3

Anti-VEGF Antibody Clone VEGF/1063, Unconjugated-100ug
7422-MSM1-P1 100ug
EUR 428

Polyclonal Goat anti-GST α-form
GST-ANTI-1 50 uL
EUR 280

Polyclonal Goat anti-GST μ-form
GST-ANTI-2 50 uL
EUR 280

Polyclonal Goat anti-GST p-form
GST-ANTI-3 50 uL
EUR 280

Human anti-hepatitis B virus e antibody(HBeAb)ELISA Kit
GA-E1619HM-48T 48T
EUR 289

Human anti-hepatitis B virus e antibody(HBeAb)ELISA Kit
GA-E1619HM-96T 96T
EUR 466

Human anti-hepatitis B virus e antibody,HBeAb ELISA Kit
201-12-1603 96 tests
EUR 440
Description: A quantitative ELISA kit for measuring Human in samples from biological fluids.

Mouse Anti-Hepatitis B Virus E Antibody (HBeAb) ELISA Kit
abx053819-96tests 96 tests
EUR 668

Human anti-hepatitis B virus e antibody, HBeAb ELISA Kit
CSB-E09570h-24T 1 plate of 24 wells
EUR 165
Description: Qualitative competitive ELISA kit for measuring Human anti-hepatitis B virus e antibody, HBeAb in samples from serum, plasma. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price.

Human anti-hepatitis B virus e antibody, HBeAb ELISA Kit
1-CSB-E09570h
  • EUR 556.00
  • EUR 3862.00
  • EUR 2060.00
  • 1 plate of 96 wells
  • 10 plates of 96 wells each
  • 5 plates of 96 wells each
Description: Qualitative competitive ELISA kit for measuring Human anti-hepatitis B virus e antibody, HBeAb in samples from serum, plasma. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits.

Human anti-hepatitis B virus e antibody(HBeAb)ELISA Kit
QY-E02515 96T
EUR 361

Hepatitis E virus (ratHEV) PCR kit
PCR-V372-48R 50T
EUR 823

Hepatitis E virus (ratHEV) PCR kit
PCR-V372-96R 100T
EUR 1113

Hepatitis B Virus E Antigen Antibody
20-abx134030
  • EUR 356.00
  • EUR 537.00
  • EUR 217.00
  • 100 ul
  • 200 ul
  • 30 ul

Hepatitis B Virus E Antigen Antibody
20-abx134031
  • EUR 356.00
  • EUR 537.00
  • EUR 217.00
  • 100 ul
  • 200 ul
  • 30 ul

Dengue virus 1 E recombinant antigen
8812 100 ug
EUR 398
Description: This is Dengue virus 1 E recombinant antigen for ELISA,WB.

Dengue virus 2 E recombinant antigen
8813 100 ug
EUR 398
Description: This is Dengue virus 2 E recombinant antigen for ELISA,WB.

Dengue virus 3 E recombinant antigen
8814 100 ug
EUR 398
Description: This is Dengue virus 3 E recombinant antigen for ELISA,WB.

Dengue virus 4 E recombinant antigen
8815 100 ug
EUR 398
Description: This is Dengue virus 4 E recombinant antigen for ELISA,WB.

Recombinant Hepatitis B Virus e-Antigen
7-07423 5µg Ask for price

Recombinant Hepatitis B Virus e-Antigen
7-07424 25µg Ask for price

Recombinant Hepatitis B Virus e-Antigen
7-07425 1000µg Ask for price

Hepatitis B Virus e-Antigen Protein
20-abx260781
  • EUR 3418.00
  • EUR 328.00
  • EUR 230.00
  • 1 mg
  • 25 ug
  • 5 ug

Hepatitis E virus RT PCR kit
RTq-H498-100R 100T
EUR 1311

Hepatitis E virus RT PCR kit
RTq-H498-150R 150T
EUR 1787

Hepatitis E virus RT PCR kit
RTq-H498-50R 50T
EUR 963

Swine HEPATITIS E virus Antibodies IgM
QY-E40197 96T
EUR 400

Swine HEPATITIS E virus Antibodies IgG
QY-E40198 96T
EUR 400

Azithromycin impurity E EvoPure®
A074-5MG 5 mg
EUR 696

ELISA kit for Rat E-Cad (E-Cadherin)
E-EL-R0347 1 plate of 96 wells
EUR 377
Description: A sandwich ELISA kit for quantitative measurement of Rat E-Cad (E-Cadherin) in samples from Serum, Plasma, Cell supernatant

CLIA kit for Mouse APO-E (Apolipoprotein E)
E-CL-M0101 1 plate of 96 wells
EUR 584
Description: A sandwich CLIA kit for quantitative measurement of Mouse APO-E (Apolipoprotein E) in samples from Serum, Plasma, Cell supernatant

CLIA kit for Mouse E-Cad (E-Cadherin)
E-CL-M0154 1 plate of 96 wells
EUR 584
Description: A sandwich CLIA kit for quantitative measurement of Mouse E-Cad (E-Cadherin) in samples from Serum, Plasma, Cell supernatant

CLIA kit for Rat E-Cad (E-Cadherin)
E-CL-R0226 1 plate of 96 wells
EUR 584
Description: A sandwich CLIA kit for quantitative measurement of Rat E-Cad (E-Cadherin) in samples from Serum, Plasma, Cell supernatant

ELISA kit for Human E-Cad (E-Cadherin)
E-EL-H0014 1 plate of 96 wells
EUR 377
Description: A sandwich ELISA kit for quantitative measurement of Human E-Cad (E-Cadherin) in samples from Serum, Plasma, Cell supernatant

ELISA kit for Mouse E-Cad (E-Cadherin)
E-EL-M0211 1 plate of 96 wells
EUR 377
Description: A sandwich ELISA kit for quantitative measurement of Mouse E-Cad (E-Cadherin) in samples from Serum, Plasma, Cell supernatant

CLIA kit for Human E-Cad (E-Cadherin)
E-CL-H0014 1 plate of 96 wells
EUR 584
Description: A sandwich CLIA kit for quantitative measurement of Human E-Cad (E-Cadherin) in samples from Serum, Plasma, Cell supernatant

Anti-VEGF Rabbit Monoclonal Antibody
M00045-1 100ug/vial
EUR 397
Description: Rabbit Monoclonal VEGF Antibody. Validated in Flow Cytometry, IP, IF, IHC, ICC and tested in Human, Mouse.

Anti-VEGF-A Humanized Antibody
A2136-100 100 µg
EUR 510

Anti-VEGF (Bevacizumab), humanized Antibody
A1045-100
EUR 501

Anti-VEGF Receptor 3 (5B6)
YF-MA10355 100 ug
EUR 363
Description: Mouse monoclonal to VEGF Receptor 3

Respiratory Syncytial Virus (RSV) is the foremost explanation for decrease respiratory tract an infection in infants, in whom, the sensing of RSV by innate immune receptors and its regulation are nonetheless poorly described. Nevertheless, the extreme bronchiolitis following RSV an infection in neonates has been related to a defect in sort I interferons (IFN-I) manufacturing, a cytokine produced primarily by alveolar macrophages (AMs) upon RSV an infection in adults. Within the current research, neonatal C57BL/6 AMs mobilized very weakly the IFN-I pathway upon RSV an infection in vitro and did not restrain virus replication.

Leave a Reply

Your email address will not be published.